Viking Therapeutics Files Q2 2024 10-Q
Ticker: VKTX · Form: 10-Q · Filed: Jul 24, 2024 · CIK: 1607678
Sentiment: neutral
Topics: 10-Q, financials, biotech, stock-plans
Related Tickers: VKTX
TL;DR
Viking Therapeutics (VKTX) Q2 10-Q filed. Cash and stock plan updates. Looks solid.
AI Summary
Viking Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial position and operational highlights. Key financial data includes cash equivalents and commercial paper holdings as of June 30, 2024, and details on employee stock plans and equity incentive plans adopted in 2014 and 2024 respectively.
Why It Matters
This filing provides investors with an update on Viking Therapeutics' financial health and corporate actions, crucial for understanding the company's operational status and future prospects.
Risk Assessment
Risk Level: medium — As a clinical-stage biopharmaceutical company, Viking Therapeutics faces inherent risks related to drug development and regulatory approvals.
Key Numbers
- 2024-06-30 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-07-24 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2023-06-30 — Prior Year Period End Date (Provides a comparative point for financial performance.)
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Filer of the 10-Q
- 20240630 (date) — End of reporting period
- 0000950170-24-086111 (accession_number) — SEC filing accession number
- 20240724 (date) — Filing date
- 9920 PACIFIC HEIGHTS BLVD, SUITE 350 (address) — Company's business and mailing address
- SAN DIEGO, CA 92121 (address) — Company's business and mailing address
- vktx:TwoThousandFourteenEmployeeStockPurchasePlanMember (plan) — Employee stock purchase plan
- vktx:TwoThousandTwentyFourEquityIncentivePlanMember (plan) — Equity incentive plan
FAQ
What was the company's cash and cash equivalents balance as of June 30, 2024?
The filing indicates 'us-gaap:CashEquivalentsMember' as of 2024-06-30, but the specific dollar amount is not provided in this header data.
When was the 2014 Employee Stock Purchase Plan established?
The 'vktx:TwoThousandFourteenEmployeeStockPurchasePlanMember' is referenced with a start date of 2014-02-01.
What is Viking Therapeutics' fiscal year end?
Viking Therapeutics' fiscal year ends on December 31.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code for Viking Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
When was the 2024 Equity Incentive Plan adopted?
The 'vktx:TwoThousandTwentyFourEquityIncentivePlanMember' is associated with the date 2024-05-21.
Filing Stats: 4,444 words · 18 min read · ~15 pages · Grade level 18.5 · Accepted 2024-07-24 17:00:23
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
Filing Documents
- vktx-20240630.htm (10-Q) — 2033KB
- vktx-ex10_1.htm (EX-10.1) — 634KB
- vktx-ex10_2.htm (EX-10.2) — 57KB
- vktx-ex10_3.htm (EX-10.3) — 155KB
- vktx-ex31_1.htm (EX-31.1) — 16KB
- vktx-ex31_2.htm (EX-31.2) — 16KB
- vktx-ex32_1.htm (EX-32.1) — 12KB
- 0000950170-24-086111.txt ( ) — 8894KB
- vktx-20240630.xsd (EX-101.SCH) — 1040KB
- vktx-20240630_htm.xml (XML) — 1383KB
Notes to Consolidated Financial Statements (unaudited)
Notes to Consolidated Financial Statements (unaudited) 5 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.
Controls and Procedures
Controls and Procedures 26 Part II. OTHER INFORMATION 28 Item 1.
Legal Proceedings
Legal Proceedings 28 Item 1A.
Risk Factors
Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 62 Item 3. Defaults Upon Senior Securities 62 Item 4. Mine Safety Disclosures 62 Item 5. Other Information 62 Item 6. Exhibits 63
FINANCI AL INFORMATION
PART I. FINANCI AL INFORMATION
Financ ial Statements
Item 1. Financ ial Statements Viking Therapeutics, Inc. Consolidated Balance Sheets (In thousands, except share and per share amounts) June 30, 2024 December 31, 2023 (Unaudited) Assets Current assets: Cash and cash equivalents $ 43,915 $ 55,516 Short-term investments – available-for-sale 898,348 306,563 Prepaid clinical trial and preclinical study costs 3,323 2,624 Prepaid expenses and other current assets 138 2,522 Total current assets 945,724 367,225 Right-of-use assets 977 1,126 Deferred financing costs 105 106 Deposits 33 33 Total assets $ 946,839 $ 368,490 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 11,090 $ 7,512 Other accrued liabilities 13,669 11,299 Lease liability, current 334 324 Total current liabilities 25,093 19,135 Lease liability, net of current portion 766 936 Total long-term liabilities 766 936 Total liabilities 25,859 20,071 Commitments and contingencies ( Note 7 ) Stockholders' equity: Preferred stock, $ 0.00001 par value: 10,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023 — — Common stock, $ 0.00001 par value: 300,000,000 shares authorized at June 30, 2024 and December 31, 2023; 110,796,200 shares issued and outstanding at June 30, 2024 and 100,113,770 shares issued and outstanding at December 31, 2023 1 1 Treasury stock at cost, no shares at June 30, 2024 and 2,193,251 shares at December 31, 2023 — ( 6,795 ) Additional paid-in capital 1,350,801 733,546 Accumulated deficit ( 427,550 ) ( 377,944 ) Accumulated other comprehensive loss ( 2,272 ) ( 389 ) Total stockholders' equity 920,980 348,419 Total liabilities and stockholders' equity $ 946,839 $ 368,490 See accompanying notes to the unaudited consolidated financial statements. 1